AdHu5Ag85A
Candidate Overview
AdHu5Ag85A (formerly Ad5Ag85A) is a recombinant type 5 human adenovirus vector which has been engineered to express Ag85A. The adenovirus construct is E1 and E3 deleted. AdHu5Ag85A consists of the MCMV promoter (start: 1724, end: 2251); tPA signal sequence (start: 1573; end: 1676); Ag85A (start: 685; end: 1572) and SV polyA signal (start: 483, end: 641). Administration is by intramuscular injection or by aerosol inhalation.
Sponsor / Lead Developer: McMaster University
Development partner(s):
CanSino Biologics
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Prevention of TB disease
Target Population(s): Adults
Target Route of Administration: Aerosol and Intramuscular
Clinical Trials
COMPLETED TRIALS |
|
| Registry Number | NCT02337270 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | McMaster University |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
Related Publications
- Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans (JCI Insight, 2022)
- Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans (J Infect Dis, 2016)
- AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates (PLOS ONE, 2015)
- A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity (Sci Transl Med, 2013)